Combining an ATR inhibitor (ATRi) with an ICI, thereby targeting an essential regulator of cell cycle checkpoints in addition to immune checkpoint pathway blockade, may synergistically activate anti-tumor immunity while minimizing the toxicity of combined therapies. Here, ATR is linked to neoplasm.